PDF(Pubmed)
Abstract：
Triple-negative breast cancer (TNBC) remains one of the most challenging subtypes since it is initially characterized by the absence of specific biomarkers and corresponding targeted therapies. Advances in methodology, translational informatics, genomics, and proteomics have significantly contributed to the identification of therapeutic targets. The development of innovative treatments, such as antibody-drug conjugates and immune checkpoint inhibitors, alongside chemotherapy, has now become the standard of care. However, the quest for biomarkers defining therapy outcomes is still ongoing. Peroxiporins, which comprise a subgroup of aquaporins, which are membrane pores facilitating the transport of water, glycerol, and hydrogen peroxide, have emerged as potential biomarkers for therapy response. Research on peroxiporins reveals their involvement beyond traditional channeling activities, which is also reflected in their cellular localization and roles in cellular signaling pathways. This research on peroxiporins provides fresh insights into the mechanisms of therapy resistance in tumors, offering potential avenues for predicting treatment outcomes and tailoring successful TNBC therapies.
摘要：
三阴性乳腺癌（TNBC）仍然是最具挑战性的亚型之一，因为它最初的特征是缺乏特定的生物标志物和相应的靶向治疗。方法论的进步，翻译信息学，基因组学，和蛋白质组学对治疗靶点的识别做出了重要贡献。创新治疗的发展，如抗体-药物偶联物和免疫检查点抑制剂，除了化疗，现在已经成为护理的标准。然而,对定义治疗结果的生物标志物的探索仍在进行中.过氧化物酶,其中包括一组水通道蛋白，它们是促进水运输的膜孔，甘油，和过氧化氢，已经成为治疗反应的潜在生物标志物。对过氧化物酶的研究表明，它们的参与超出了传统的通道活动，这也反映在它们的细胞定位和在细胞信号通路中的作用。这项关于过氧化物酶的研究为肿瘤治疗抵抗的机制提供了新的见解，为预测治疗结果和定制成功的TNBC疗法提供了潜在的途径。
